

## A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

Wolfgang Wick<sup>1,2</sup>, Harald Fricke<sup>3</sup>, Klaus Junge<sup>4</sup>, Grigory Kobayakov<sup>5</sup>, Tobias Martens<sup>6</sup>, Oliver Heese<sup>6</sup>, Benedikt Wiestler<sup>1,2</sup>, Maximilian G. Schliesser<sup>2</sup>, Andreas von Deimling<sup>7,8</sup>, Josef Pichler<sup>9</sup>, Elena Vetlova<sup>5</sup>, Inga Harting<sup>10</sup>, Jürgen Debus<sup>11</sup>, Christian Hartmann<sup>7,8</sup>, Claudia Kunz<sup>3</sup>, Michael Platten<sup>1,12</sup>, Martin Bendszus<sup>10</sup>, and Stephanie E. Combs<sup>11</sup>

### Abstract

**Purpose:** Preclinical data indicate anti-invasive activity of APG101, a CD95 ligand (CD95L)-binding fusion protein, in glioblastoma.

**Experimental Design:** Patients ( $N = 91$ ) with glioblastoma at first or second progression were randomized 1:2 between second radiotherapy (rRT; 36 Gy; five times 2 Gy per week) or rRT+APG101 (400 mg weekly i.v.). Patient characteristics [ $N = 84$  (26 patients rRT, 58 patients rRT+APG101)] were balanced.

**Results:** Progression-free survival at 6 months (PFS-6) rates were 3.8% [95% confidence interval (CI), 0.1–19.6] for rRT and 20.7% (95% CI, 11.2–33.4) for rRT+APG101 ( $P = 0.048$ ). Median PFS was 2.5 (95% CI, 2.3–3.8) months and 4.5 (95% CI, 3.7–5.4) months with a hazard ratio (HR) of 0.49 (95% CI, 0.27–0.88;  $P = 0.0162$ ) adjusted for tumor size. Cox regression analysis adjusted for tumor size revealed a HR of 0.60 (95% CI, 0.36–1.01;  $P = 0.0559$ ) for rRT+APG101 for death of any cause. Lower methylation levels at CpG2 in the *CD95L* promoter in the tumor conferred a stronger risk reduction (HR, 0.19; 95% CI, 0.06–0.58) for treatment with APG101, suggesting a potential biomarker.

**Conclusions:** CD95 pathway inhibition in combination with rRT is an innovative concept with clinical efficacy. It warrants further clinical development. *CD95L* promoter methylation in the tumor may be developed as a biomarker. *Clin Cancer Res*; 20(24); 6304–13. ©2014 AACR.

### Introduction

Treatment regimens used for progressive glioblastoma are of very limited efficacy (1–3). For years, alkylating chemotherapy has been the mainstay, although patients already had been exposed to temozolomide in conjunc-

tion with radiotherapy after diagnosis and surgery. Lomustine (CCNU) is commonly used at progression. Recent and ongoing trials tested anti-vascular endothelial growth factor (VEGF; receptor) strategies (4, 5), protein kinase C- $\beta$  inhibition with enzastaurin (6)

<sup>1</sup>Department of Neurooncology, Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.

<sup>2</sup>Clinical Cooperation Unit—Neurooncology, German Consortium of Translational Cancer Research (DKTK), German Cancer Research Center, Heidelberg, Germany. <sup>3</sup>Apogenix GmbH, Heidelberg, Germany. <sup>4</sup>Premier Research Germany Ltd., Darmstadt, Germany. <sup>5</sup>Burdenko Neurosurgery Research Institute, Moscow, Russia. <sup>6</sup>Clinic for Neurosurgery, University Clinic Hamburg-Eppendorf, Hamburg, Germany. <sup>7</sup>Clinical Cooperation Unit—Neuropathology, German Consortium of Translational Cancer Research (DKTK), German Cancer Research Center, Heidelberg, Germany. <sup>8</sup>Institute of Neuropathology, University Clinic Heidelberg, Heidelberg, Germany. <sup>9</sup>Department of Internal Medicine and Neurooncology, Landesnervenklinik Linz, Austria. <sup>10</sup>Department of Neuroradiology, Neurology Clinic and Radiology Clinic, University Hospital Heidelberg, Heidelberg, Germany. <sup>11</sup>Department of Radiation Oncology, Radiology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany. <sup>12</sup>Clinical Cooperation Unit—Neuroimmunology and Brain Tumour Immunology, German Consortium of Translational Cancer Research (DKTK), German Cancer Research Center, Heidelberg, Germany.

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

M. Platten, M. Bendszus, and S.E. Combs contributed equally to this article.

Current address for O. Heese: Department of Neurosurgery, HELIOS Medical Center Schwerin, Schwerin, Germany; current address for C. Hartmann: Department for Neuropathology, Institute of Pathology, Medical University of Hannover, OE 5110, Hannover, Germany.

Prior presentation: An analysis of the primary endpoint was presented at the ASCO Meeting 2012: Bendszus M, Debus J, Wick W, et al. *J Clin Oncol* 2012, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2012; 28[18 suppl (June 20 Supplement)]: abstract nr. 2034; Further data except for the methylation data have been presented at the ECCO Meeting 2013: Wick W, Debus J, Bendszus M, et al. *Eur J Cancer* 2013; abstract nr. 3304 and ASCO Meeting 2014: Platten M, Fricke H, Junge K, et al. *J Clin Oncol* 2014, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2014; 32 [5 suppl]: abstract nr. 2006.

**Corresponding Author:** Wolfgang Wick, Department of Neurooncology, Neurology Clinic and National Center for Tumor Diseases, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany. Phone: 49-6221-56-7075; Fax: 49-6221-56-7554; E-mail: [wolfgang.wick@med.uni-heidelberg.de](mailto:wolfgang.wick@med.uni-heidelberg.de)

doi: 10.1158/1078-0432.CCR-14-0951-T

©2014 American Association for Cancer Research.

### Translational Relevance

Inhibiting rather than inducing CD95 activity is a break-of-paradigm treatment approach for malignant gliomas. APG101 in combination with radiotherapy is a concept with good tolerability and clinical efficacy in patients with progressive glioblastoma. *CD95L* promoter methylation in the tumor tissue may be developed as a biomarker.

or they embarked on various temozolomide regimens (7, 8).

With the recognition that tissue recovery in the brain after radiotherapy might be much better than initially thought, options for a second radiotherapy (rRT) were explored. Retrospective analyses or uncontrolled trials reported positive clinical outcomes (9, 10). There is no consensus on one particular radiation regimen, but different concepts of hypofractionation, target delineation, and dosing, for example,  $18 \times 2$  Gy,  $15 \times 2.33$  Gy,  $6 \times 5$  Gy, exist.

CD95 (Fas, APO-1) is a pleiotropic receptor that regulates tissue homeostasis. During cancer progression, CD95 is frequently downregulated or tumor cells are rendered apoptosis resistant. However, evidence exists that cancer cells, regardless of their CD95 apoptosis sensitivity, depend on constitutive activation of CD95 for optimal growth (11), stimulated by CD95 ligand (CD95L) produced in an autocrine or paracrine manner. A growth-promoting role of the CD95/CD95L system has recently been described for glioblastoma *in vitro* and in an orthotopic syngeneic mouse model (12, 13) where activation of CD95 by CD95L stimulates AKT kinase- and  $\beta$ -catenin-dependent genes (12). CD95 activation in glioblastoma leads to invasive growth and migration facilitated by increased expression of matrix metalloproteinases (MMP), which are key mediators of glioma invasiveness (13). *In vitro*, blocking of CD95 activation was demonstrated to impede increased invasiveness of irradiated glioblastoma cells as an adaptive evasive response to radiation (14, 15). This insidious effect of radiotherapy may be mediated by stimulation of PI3K/AKT-dependent MMP-2 and MMP-9 activity (16, 17) or alternative mechanisms (18). APG101 is a CD95L-binding protein consisting of the extracellular domain of human CD95 fused to the Fc region of human IgG1. It interferes with CD95-dependent signaling by binding to CD95L, thereby blocking subsequent CD95-dependent activation (19). The possibility exists that not only cell-bound CD95L, but soluble, potentially systemic (20) as well as endothelial cell-bound CD95L may also serve as a therapeutic target (21). Single ascending doses of APG101 up to 20 mg/kg body weight (bw) administered as infusion over 1 hour were considered as safe and well tolerated in healthy volunteers in a phase I study. No maximum tolerated dose (MTD) has been reached and no anti-drug antibodies (ADA) were detected. After the application of multiple doses of 400 mg

in 2 patients with glioma under compassionate use conditions, steady state for APG101 seemed to be reached, supporting further clinical evaluation of APG101 at a dose of 400 mg per week in patients with glioblastoma (19).

From the above, the combination of APG101 and radiotherapy might be particularly attractive, because APG101 might enhance radiation efficacy and reduce unwanted radiation-induced infiltrative growth, and radiotherapy might facilitate the delivery of APG101 to the tumor stroma by opening the blood-brain barrier (BBB). The primary objective of this phase II study was to evaluate the efficacy as determined by progression-free survival at 6 months (PFS-6) for patients with first or second progression of a glioblastoma. Secondary objectives included safety and tolerability of APG101, response rate (RR), overall survival (OS), PFS, and health-related quality of life. There were also correlative studies planned to find a tissue-based biomarker by immunohistochemistry.

## Patients and Methods

### Patients

Adult patients with first or second progression of a histologically confirmed glioblastoma either not being eligible for tumor resection or having macroscopic residual tumor after tumor resection, documented by contrast-enhanced magnetic resonance imaging (MRI) with the largest diameter measuring 1 to 4 cm and a Karnofsky performance score (KPS)  $\geq 60$  were eligible. No more than two prior therapy regimens including one or two resections, one or two chemotherapies of which one must have been temozolomide-containing, and one radiotherapy (completed  $\geq 8$  months before enrollment) were allowed. All patients were required to give signed informed consent before enrollment.

### Trial design and conduct

The APG101\_CD\_002 study (NCT01071837) followed a Simon two-stage design. A randomized control arm with rRT alone was added to avoid under- or overestimation of a signal from APG101. The study was approved by the ethics committees (EC) of all 25 participating sites. The study started recruitment in December 2009, and the last patient was randomized on Sep 21, 2011. Patients were centrally randomized 1:2 to receive rRT (36 Gy) or rRT (36 Gy) + APG101 400 mg weekly until progression (Fig. 1). Treatment following disease progression was recorded.

In this open-label, multinational trial, the first 9 patients constituted a predefined run-in phase to evaluate the safety of rRT + APG101. An independent Data and Safety Monitoring Board (DSMB) reviewed all relevant patient data after completion of the rRT and endorsed further accrual to the trial. The second meeting was held after 25 patients completed the reirradiation (rRT) and the third took place at the end of stage 1 of the Simon two-stage design (after 28 patients reached the primary endpoint) combined with a safety evaluation after the first 49 patients completed rRT.

At the submission of this article, the collection of OS data is still ongoing. The study adhered to the Declaration




Figure 1. Trial design and CONSORT flow chart. Patients were randomized 1:2 to receive rRT or rRT+APG101.

of Helsinki and the Guideline for Good Clinical Practice (ICH-GCP). Intensity of adverse events (AE) was assessed as mild/moderate/severe.

### Radiotherapy

rRT at 36 Gy in 2-Gy single fractions was required to be performed as highly precise treatment, either as a stereotactic radiotherapy or as an image-guided radiotherapy. To assess the quality of each participating center, a dedicated dummy run evaluating technical equipment, quality assurance as well as treatment planning was performed. Only centers fulfilling all requirements were eligible to recruit patients into the trial. To ensure protocol-conform treatment planning, 2 test patients were distributed to each center and target volume definition as well as treatment planning and dose distributions carried out by the site were evaluated as a dummy run (Medical Centre Heidelberg, Heidelberg, Germany). In detail, as the basic inclusion criterion was an indication for rRT, any recurrence in- or outside the radiation field that occurred  $\geq 8$  months out of the initial RT was principally eligible. However, because  $>90\%$  of the lesions occur inside the radiation volume, all except 1 patient, who had a recurrence at the 20% isodose, had a pre-RT at a similar region. For treatment planning, CT and contrast-enhanced MRI were mandatory. Target volume delineation was defined to include the gross tumor

volume (GTV) defined as the contrast-enhancing lesion on MRI, adding 1 cm safety margin for potential microscopic spread (clinical target volume, CTV). After treatment, treatment plans of study patients were reviewed centrally in Heidelberg and protocol adherence was confirmed for all patients.

### APG101

APG101 was given at 400 mg weekly as a 30-minute i.v. infusion until progression or undue toxicity. It was started on the same day as the rRT. APG101 was applied before rRT due to potential compliance reasons, for example, patients might be tired after the RT and therefore refuse the APG101 infusion on this day, which should be avoided.

### Randomization and masking

Participant allocation was done according to an electronically generated randomization list stratified for maximum tumor diameter ( $\leq 2.5$  vs.  $> 2.5$  cm), a risk factor established for reirradiation (9). The sequence was generated before the start of study at the Contract Research Organization (CRO), Premier Research (Darmstadt, Germany).

Allocation took place by fax transmission from the CRO to the study site for patients fulfilling the eligibility criteria. This was an unblinded trial. Biases were prevented by strict adherence to an analysis plan that was written by the statistician (K. Junge) before any analysis of the data.

### Evaluations

Baseline examinations included physical examination, vital signs, MRI, full blood cell counts, blood chemistry, serology (HbsAG, anti-HCV, and anti-HIV), urine analysis, ECG, abdominal ultrasound, Mini-Mental State Examination (MMSE), structured neurologic examination, and quality-of-life questionnaire (QLQ) assessment with European Organisation for Research and Treatment of Cancer (EORTC) EORTC QLQ-C15 PAL questionnaire and the brain module EORTC QLQBN-20 (22).

Patients randomized to rRT only had to attend 6-weekly visits; patients in the rRT+APG101 arm had weekly visits with i.v. application of APG101.

Toxicity/AEs, safety laboratory (blood chemistry and hematology), vital signs, and Karnofsky index were assessed at every visit (weekly in APG101+rRT patients, 6-weekly in rRT-only patients). A more comprehensive evaluation that included physical examination, MRI, MMSE, structured neurologic examination, and QLQ was carried out every 6 weeks for all patients. Urine analysis, ECG, and abdominal ultrasound were done every 12 weeks.

Sites had to complete an MRI dummy run before study start for quality reasons. Tumor response or progression was defined according to modified MacDonald criteria taking pseudoprogression into account (23) by the local investigator and centrally. In detail, an apparent increase in tumor size considering the largest cross-sectional area or contrast-enhancement in the radiation field of  $\geq 25\%$  in the first or second scan post-rRT was called pseudoprogression and not deemed a progression until further confirmation on follow-

up. As recommended in the RANO criteria (24), minimal clinical worsening or increase in steroids (up to 4 mg) was not considered inconsistent with the diagnosis of pseudo-progression. Further progression resulted in backdating to the scan of the initial suspicion of a progression and stable disease on follow-up in retrospective rating as stable. Stable or decreasing contrast enhancement resulted in a continuation of trial treatment and/or follow-up. Further prespecified analyses of all patients were done for all irradiation plans (S.E. Combs and J. Debus) and tissue quality before molecular examinations (C. Hartmann and A. von Deimling) in a blinded fashion (25).

### Neuropathologic methods

Archived tumor tissue was available from 81 patients. This tumor tissue was used to examine *IDH1*, O6-methylguanine-DNA methyl-transferase (*MGMT*), CD95, and CD95L as well as genome-wide methylation levels in a discovery set of 20 tumor samples.

Only solid tumor tissue was evaluated. Areas that showed an infiltration zone or non-neoplastic brain parenchyma were excluded from the evaluation process. Expression of mutated *IDH1* R132H protein was determined by immunohistochemistry (26). The *MGMT* promoter methylation status was analyzed after bisulfite treatment by methylation-specific PCR (27). Expression of CD95 and CD95L was determined by immunohistochemistry.

All CD95- and CD95L-stained slides were evaluated slide-by-slide in a single session by a board-certified neuropathologist (C. Hartmann). Vital tumor tissue of each slide was evaluated regarding the CD95 and CD95L staining intensities "high," "moderate," "low," and "absent." CD95 and CD95L calibration figures were used to standardize the evaluation. Because most tumors showed different staining intensities in separate areas, the percentage of these summed areas were counted. Each tumor was assigned to a specific value in percentage representing the area showing "high," "moderate," "low," and "absent" CD95 and CD95L staining intensities.

CD95L promoter methylation by MassARRAY at probes cg10161121 (CpG2) and cg06983746 (CpG1) was then examined in a validation set of 40 patients. For clinical data evaluations, a median-based cutoff at 0.85 was used (see Supplementary Methods and Supplementary Tables S3–S8).

### Biomarker identification

To identify epigenetic differences distinguishing responders from non-responders, we performed genome-wide assessment of DNA methylation using the HumanMethylation450 BeadChip (Illumina) of 20 patients who received APG101 plus radiotherapy (10 patients with a PFS > 5 months and 10 patients with a PFS < 2 months, discovery cohort) at the Genomics and Proteomics Core Facility of the German Cancer Research Center (Heidelberg, Germany). Data normalization was performed following the manufacturer's recommendations. Unsupervised hierarchical clustering was performed after removing probes (i) target-

ing the X and Y chromosomes, (ii) containing a single-nucleotide polymorphism within 5 base pairs and including the CpG site, and (iii) not mapping uniquely to the human reference genome (hg19), allowing for one mismatch. The Student *t* test assuming unequal variances was used to detect probes with significantly different mean methylation between the two groups.

### Biomarker validation

Two CpGs upstream of the CD95L were screened in an independent validation cohort comprising all patients for whom sufficient DNA was available and who were not part of the discovery cohort ( $n = 40$  patients) using the MassARRAY technique (Sequenom). This technology relies on detection of mass shifts, which are introduced through sequence changes following bisulfite treatment. In short, 500 ng genomic DNA was bisulfite-converted using the Epiect Bisulfite Kit (Qiagen). For PCR amplification, the following primers were used:

```
aggaagagagTTATTTGTAGTTGAAGTTGAGAAG (forward)
cagtaatcgcactactataggagaaggctACTAACCTACTCTACAAA-
ATCCC (reverse)
```

Next, DNA methylation analysis was performed on a Sequenom mass spectrometer and the results were analyzed by the EpiTyper software (Version 1.05; Sequenom). For statistical analysis, both CpGs were dichotomized using their median methylation level, and Cox regression analysis using a model including tumor size (the main prognostic factor in the analysis of the trial data) and treatment (APG101+ radiotherapy vs. radiotherapy alone) was performed.

### Statistical analysis

The primary endpoint was the proportion of patients free of progression based on the central assessment and alive at 6 months (PFS-6), calculated in days from randomization.

The sample size of the study was planned according to the optimal two-stage design of Simon (28) for the rRT+APG101 arm with a PFS-6 target rate of 30%, a noninteresting rate of 15%, first-type error rate of 0.05, and a power of 80%. A control arm of patients treated with rRT alone was added to the Simon design to calibrate the PFS-6 rate. The sample size of the control arm was defined as 50% of the investigational treatment arm. The Simon design required the recruitment of 55 patients for the rRT+APG101 arm (19 patients in stage I and 36 patients in stage II). With the addition of 28 patients in the control arm, the study was hence planned with a total sample size of 83 patients.

The study was not powered for comparisons between treatment arms. According to the Simon design, the study was considered positive if 13 PFS-6 responses were observed among the 55 patients treated with rRT+APG101, based on the specified target and noninteresting rate.

Secondary efficacy endpoints were: objective RRs, OS, PFS, quality-of-life as determined by EORTC PAL QLQ-C15 and -BN20, and cognitive function determined by MMSE. Safety and tolerability of APG101 were assessed by AEs with intensity mild/moderate/severe. PFS was defined as time from randomization to next progression for patients with progression or, respectively, as time to death of any cause for patients without progression described with Kaplan–Meier estimates. Patients without progression or death were censored at the day of the last assessment of tumor response. The significance level for remarkable findings was set to 0.05 for all tests in this study.

Within the framework of prospectively planned descriptive analyses:

- exact 95% confidence intervals (CI) according to Clopper–Pearson were calculated for the rates within treatment groups and asymptotic 95% CI were presented for the difference of rates between treatment groups. Descriptive treatment comparisons of rates were done by use of a Fisher test.
- Kaplan–Meier estimates (3) were used to describe PFS and OS and derive median survival times together with 95% CI. Cox regression models including prognostic factors tumor size (29) and proliferation rate, Karnofsky performance status (60–80 vs. 90–100), CD95 status (proportion of moderate + high), and CD95L status (proportion of moderate + high) as covariates were fitted to PFS and OS data to obtain estimates of treatment hazard ratios (HR) and corresponding 95% CI.

All analyses of the primary and secondary efficacy endpoints were based on the intention-to-treat (ITT) population, which included all randomized patients except patients who did not receive any dose of trial medication or rRT after randomization. The *per-protocol* analyses were limited to patients without major protocol violations (Fig. 1).

The safety analyses were done on the entire documentation of AEs (details in Supplementary Methods). Changes in Quality of Life scores with respect to baseline were classified as improved, unchanged, and worsened. Asymptotic 95% CI were calculated for the differences in improvement rates between treatment groups by visit.

Analyses were performed with SAS 9.1.3 (SAS Institute). During the study, the data were documented into the Oracle Clinical data management system of Premier Research (Darmstadt, Germany). Premier Research monitored the data quality. This trial is registered with ClinicalTrials.gov (NCT01071837).

## Results

### Patients

The trial enrolled and randomized 91 patients. The ITT population included 84 patients who were randomized and received at least one dose of APG101 or rRT. The *per-protocol* population consisted of 72 patients (Fig. 1). As of the data

**Table 1.** Baseline patient and disease characteristics

Characteristic	rRT (n = 26)	rRT + APG101 (n = 58)
Median age, y (range)	59 (25–79)	57 (20–73)
Sex, n (%)		
Male	12 (46.2)	39 (67.2)
Karnofsky performance status, n (%)		
60–80	8 (30.8)	17 (29.3)
90–100	18 (69.2)	41 (70.7)
MGMT status, n (%)		
Methylated	15 (57.7)	41 (70.6)
Nonmethylated	8 (30.8)	14 (24.1)
Missing	3 (11.5)	3 (5.2)
IDH status, n (%)		
Mutated	0	6 (10.3)
Wild-type	25 (96.2)	49 (84.5)
Missing	1 (3.8)	3 (5.2)
Recurrence status, n (%)		
First	19 (73.1)	41 (70.7)
Second	6 (23.1)	15 (25.9)
Third	1 (3.8)	2 (3.4)
Mean time since first diagnosis, mo (SD)	20.3 (11.7)	23.9 (14.8)
Tumor diameter, n (%)		
≤2.5 cm	20 (76.9)	29 (50)
>2.5 cm	6 (23.1)	29 (50)
CD95L status, n (%)		
Positive	16 (61.5)	39 (67.2)
Negative	8 (30.8)	16 (27.6)
Missing	2 (7.7)	3 (5.2)

cutoff date (June 7, 2013), median follow-up was 11.4 months in both treatment arms. Baseline patient and disease characteristics were well balanced (Table 1).

### Tolerability and toxicity

Most patients tolerated both treatments well. Toxicities are listed in Table 2. There were three patients in the rRT arm who discontinued rRT due to disease progression and one patient receiving 20 fractions. All other patients (22 of 26; 84.6%) received the planned 18 × 2 Gy. In the rRT+APG101 arm, all patients except of 1 received the planned RT (57 of 58; 98.3%). The median duration of APG101 treatment was 3.6 months (range, 0.1–24 months). Discontinuations from the study occurred because of disease progression (67 of 84; 79.8%), withdrawal of consent (2 of 84; 2.4%), investigator judgment (7 of 84; 8.3%), withdrawal from treatment (4 of 84; 4.8%), and other reasons (4 of 84; 4.8%).

### Efficacy outcomes

At a minimal follow-up of 6 months [median 11.4 months (range, 2–36+ months)] after the last patient had

**Table 2.** Number of patients with AEs by maximal severity and MedDRA preferred term (frequency of AEs  $\geq 10.0\%$  of the total patients by preferred term)

Number of patients with AE by MedDRA preferred term	APG101 + <sup>a</sup> (n = 58) n (%)			a (n = 26) n (%)			Total (n = 84) n (%)		
	Mild	Mod.	Severe	Mild	Mod.	Severe	Mild	Mod.	Severe
Any AE	9 (15.5)	27 (46.6)	22 (37.9)	3 (11.5)	9 (34.6)	13 (50.0)	12 (14.3)	36 (42.9)	35 (41.7)
Nervous system disorders	12 (20.7)	31 (53.4)	11 (19.0)	4 (15.4)	8 (30.8)	10 (38.5)	16 (19.0)	39 (46.4)	21 (25.0)
Aphasia	2 (3.4)	2 (3.4)	3 (5.2)	0 (0.0)	4 (15.4)	1 (3.8)	2 (2.4)	6 (7.1)	4 (4.8)
Brain edema	2 (3.4)	7 (12.1)	0 (0.0)	2 (7.7)	4 (15.4)	1 (3.8)	4 (4.8)	11 (13.1)	1 (1.2)
Cognitive disorder	2 (3.4)	5 (8.6)	2 (3.4)	2 (7.7)	1 (3.8)	0 (0.0)	4 (4.8)	6 (7.1)	2 (2.4)
Convulsion	2 (3.4)	5 (8.6)	3 (5.2)	2 (7.7)	1 (3.8)	2 (7.7)	4 (4.8)	6 (7.1)	5 (6.0)
Coordination abnormal	3 (5.2)	6 (10.3)	2 (3.4)	2 (7.7)	1 (3.8)	0 (0.0)	5 (6.0)	7 (8.3)	2 (2.4)
Headache	13 (22.4)	13 (22.4)	1 (1.7)	4 (15.4)	2 (7.7)	1 (3.8)	17 (20.1)	15 (17.9)	2 (2.4)
Hemiparesis	3 (5.2)	4 (6.9)	3 (5.2)	0 (0.0)	3 (11.5)	3 (11.5)	3 (3.6)	7 (8.3)	6 (7.1)
Hypoaesthesia	8 (13.8)	0 (0.0)	0 (0.0)	2 (7.7)	2 (7.7)	0 (0.0)	10 (11.9)	2 (2.4)	2 (2.4)
Motor dysfunction	2 (3.4)	5 (8.6)	0 (0.0)	2 (7.7)	0 (0.0)	0 (0.0)	4 (4.8)	5 (6.0)	0 (0.0)
Neurologic decompensation	0 (0.0)	4 (6.9)	2 (3.4)	1 (3.8)	1 (3.8)	5 (19.2)	1 (1.2)	5 (6.0)	7 (8.3)
Partial seizures	5 (8.6)	6 (10.3)	0 (0.0)	0 (0.0)	1 (3.8)	1 (3.8)	5 (6.0)	7 (8.3)	1 (1.2)
General disorders and administration site conditions	12 (20.7)	14 (24.1)	7 (12.1)	0 (0.0)	6 (23.1)	7 (26.9)	12 (14.3)	20 (23.8)	14 (16.7)
Disease progression	1 (1.7)	1 (1.7)	4 (6.9)	0 (0.0)	1 (3.8)	4 (15.4)	1 (1.2)	2 (2.4)	8 (9.5)
Fatigue	4 (6.9)	11 (19.0)	0 (0.0)	3 (11.5)	3 (11.5)	1 (3.8)	7 (8.3)	14 (16.7)	0 (0.0)
General physical health deterioration	0 (0.0)	4 (6.9)	2 (3.4)	0 (0.0)	3 (11.5)	1 (3.8)	0 (0.0)	7 (8.3)	3 (3.6)
Gastrointestinal disorders	20 (34.5)	7 (12.1)	1 (1.7)	6 (23.1)	3 (11.5)	1 (3.8)	26 (31.0)	10 (11.9)	2 (2.4)
Nausea	7 (12.1)	4 (6.9)	0 (0.0)	3 (11.5)	0 (0.0)	0 (0.0)	10 (11.9)	4 (4.8)	0 (0.0)
Vomiting	7 (12.1)	2 (3.4)	0 (0.0)	1 (3.8)	0 (0.0)	0 (0.0)	8 (9.5)	2 (2.4)	0 (0.0)
Musculoskeletal and connective tissue disorders	11 (19.0)	9 (15.5)	1 (1.7)	0 (0.0)	2 (7.7)	1 (3.8)	11 (13.1)	11 (13.1)	2 (2.4)
Pain in extremity	4 (6.9)	3 (5.2)	1 (1.7)	0 (0.0)	1 (3.8)	0 (0.0)	4 (4.8)	4 (4.8)	1 (1.2)
Investigations	10 (17.2)	6 (10.3)	2 (3.4)	3 (11.5)	2 (7.7)	1 (3.8)	13 (15.5)	8 (9.5)	3 (3.6)
Karnofsky scale worsened	5 (8.6)	2 (3.4)	0 (0.0)	1 (3.8)	2 (7.7)	0 (0.0)	6 (7.1)	4 (4.8)	0 (0.0)
Psychiatric disorders	9 (15.5)	6 (10.3)	2 (3.4)	4 (15.4)	4 (15.4)	0 (0.0)	13 (15.5)	10 (11.9)	2 (2.4)
Depression	3 (5.2)	2 (3.4)	1 (1.7)	1 (3.8)	2 (7.7)	0 (0.0)	4 (4.8)	4 (4.8)	1 (1.2)

Abbreviations: N, number of patients; Mod, moderate.

<sup>a</sup>Patients in the rRT+APG101 arm have been seen weekly during the post-rRT phase until progression, whereas patients in the rRT arm were seen 6-weekly.

been randomized, 84 patients were evaluable for the primary endpoint. In the control arm, rRT resulted in a PFS-6 rate of 3.8% (95% CI, 0.1–19.6), that is, one patient was free of progression, whereas PFS-6 in the rRT+APG101 arm was 20.7% (95% CI, 11.2–33.4), that is, 12 patients, one less than prespecified, were free of progression. The difference in PFS-6 rates was 16.9% (95% CI, 4.1–29.6;  $P = 0.0485$ ,  $\chi^2$  test). These data were confirmed in the central review.

Efficacy of rRT+APG101 was also suggested by the analysis of the *per-protocol* population (Fig. 1) for PFS-6 with 4.8% (95% CI, 0.1–23.8) and 21.6% (95% CI, 11.3–35.3;  $P = 0.1606$ ).

Median PFS was 2.5 months (95% CI, 2.3–3.8) and 4.5 months (95% CI, 3.7–5.4,  $P = 0.0162$ ; Fig. 2A).

In the univariate analysis, median OS was 11.5 (95% CI, 6.5–15.4) months in the rRT+APG101 and 11.5 (95% CI, 8.8–16.2) months in the rRT arm (Fig. 2B). After correcting for tumor size, the HR for the secondary endpoint OS was 0.60 (95% CI, 0.36–1.01;  $P = 0.0559$ ; Table 3).

In both arms, all patients experienced progression in the observation interval of the study. Pseudoprogression (21) was reported in 19 of 26 (73.1%) patients in the rRT and in 43 of 58 (74.1%) patients in the rRT+APG101 arm. It was confirmed in 8 of 19 and 22 of 43 patients, respectively (see Supplementary Table S1). Patients in both arms had similar types and frequencies of salvage therapies. These postprogression treatments are listed in the Supplementary Table S2.

### Prognostic and predictive factors

Tumor size  $\leq 2.5$  cm at rRT was a prognostic factor for OS with HR = 0.45 (95% CI, 0.27–0.75;  $P = 0.0022$ ) and for PFS with a HR = 0.61 (95% CI, 0.35–1.05;  $P = 0.0744$ ; Table 3), but not proliferation rate or KPS. Tumor tissue was analyzed for *IDH1 R132H* mutation (7 of 84; 8.4%; Supplementary Table S3), *MGMT* promoter methylation (57 of 84; 67.9%; Supplementary Table S4), expression of CD95 (Supplementary Table S6) and the APG101 target CD95L (Supplementary Table S7), as well as CpG methylation analysis upstream of *CD95L* (Supplementary Fig. S1). Lower methylation at CpG2 in the *CD95L* promoter was a positive prognostic factor for PFS and OS in the rRT+APG101 arm (Supplementary Table S8 and Supplementary Fig. S2).

### Quality-of-life assessments

Health-related quality of life (22) data were available from 92% of all patients. No clinically meaningful or statistically remarkable differences between the two groups over time in any of the scales or cohorts were observed. Baseline values and the last values available are depicted in Supplementary Table S9.

### Discussion

The present trial evaluated a novel therapeutic approach for recurrent glioblastoma aiming to silence the proinvasive CD95/CD95L system. The fusion protein APG101 hereby




Figure 2. Kaplan-Meier survival estimates. Data of PFS (A) or OS (B) were analyzed by treatment arm.

acts as a CD95L scavenger. The addition of APG101 to rRT produces a promising number of patients with first or second progression of a glioblastoma eligible for rRT without progression at 6 months after randomization. Within the borders of the randomized non-comparative design of our trial, there is a beneficial PFS signal and also promising OS data after correction for tumor size. Patients with low methylation at CpG2 upstream of *CD95L* seemed to have a greater benefit from the addition of APG101 to rRT (Supplementary Fig. S2). Thus, *CD95L* promoter methylation may be developed as a selection marker. Expression of CD95L (Supplementary Fig. S3) seems to be associated with impaired prognosis in other malignancies as well (30).

**Table 3.** Efficacy outcomes (ITT)<sup>a</sup>

	rRT (n = 26)	rRT + APG101 (n = 58)
PFS-6 rate (95% CI)	3.8% (0.1–19.6)	20.7% (11.2–33.4)
Median PFS, mo (95% CI)	2.5 (2.3–3.8)	4.5 (3.7–5.4)
Median PFS, HR (95% CI)	0.49 (0.27–0.88)	
	(P = 0.0162 after correction for tumor size)	
Median OS, mo (95% CI)	11.5 (6.5–15.4)	11.5 (8.8–16.2)
Median OS, HR (95% CI)	0.60 (0.36–1.01)	
	(P = 0.0559 after correction for tumor size)	

<sup>a</sup>Exploratory analyses due to the non-comparative design of the trial.

The main reason for a poor outcome in glioblastoma is therapy resistance, the highly invasive behavior as well as the local immunosuppression. Although for patients with newly diagnosed glioblastoma the current standard of care is radiochemotherapy with temozolomide, no such standard exists for progressive disease. Therapeutic options at recurrence depend on the individual disease situation and include reoperation, rRT, alkylating chemotherapy with temozolomide or nitrosoureas, bevacizumab, and experimental agents within clinical trials. Approaches targeting the pathologic tumor vasculature are numerous and bevacizumab was approved in the United States and in countries outside the European Union. All other compounds addressing this concept recently failed in phase II/III evaluations, including the VEGF receptor 2 inhibitor cediranib (4), the protein kinase C inhibitor enzastaurin (6), the VEGF trap aflibercept (31), and the integrin inhibitor cilengitide (32) as well as a series of trials analyzing the efficacy of epidermal growth factor receptor inhibition (33). By targeting the invasive growth, APG101 addresses a pathologic hallmark of glioblastoma different from all previous approaches.

In uncontrolled series of rRT with fractionated stereotactic rRT (9, 10) or stereotactic radiosurgery (34), rRT appeared as a relatively safe and effective approach in well-selected patient groups as one option for salvage therapy. Because exposure of glioblastoma cells to RT induces upregulation of CD95L, the combination of rRT with APG101 should improve the efficacy of RT, as was demonstrated in preclinical experiments (35).

In the current trial, the PFS-6 rate (12 of 56 patients) of rRT+APG101 is remarkable given the prespecified target (13 of 56 patients) corrected for the performance of the rRT arm that was lower than assumed, but well within the range for recurrent therapy trials. Patients received similar post-progression treatments in both study arms (Supplementary Table S2). The positive PFS signal (Fig. 2A) also translates into a meaningful OS benefit in the rRT +APG101 arm (Fig. 2B). The macroscopic diameter of the tumor, as determined by MRI, is strongly prognostic. Hence, a neurosurgic reduction of the tumor size may be an adequate measure enabling patients to achieve a greater benefit from the combined treatment with APG101 + rRT.

RRT+APG101 was well tolerated (Table 2). There were no serious AEs causally related to APG101, and APG101 did not impair tolerability of rRT resulting in a favorable risk/benefit assessment. Radiotherapy increases the permeability of the BBB, which may lead to edema and potentially worsening of neurologic symptoms. An increased BBB permeability may facilitate APG101 influx into the tumor stroma and the invasive tumor front.

The present phase II proof-of-concept study was designed to identify a therapeutic effect of APG101 when combined with rRT in the treatment of progressive glioblastoma. Thus, the study population was selected for smaller tumors and a long interval from first or second progression as needed for a second RT. The latter is documented by the high number of patients with *MGMT* promoter methylation (Table 1). There were insignificant imbalances in favor of the rRT+APG101 arm with more *IHD*-mutant tumors and in favor of the rRT arm with smaller tumors (Table 1). However, only 2 of the patients who reached PFS-6 had an isocitrate dehydrogenase (*IDH*)-mutant tumor. Every effort was made to ensure high quality and comparability of therapeutic and diagnostic measures applied during the study. MRI and RT dummy runs had to be completed by all sites and all sites had to obtain central approval before participation in the study. MRIs were assessed centrally in a blinded fashion and a strict algorithm to identify pseudo-progression was used. All measures ensured the accuracy of the observed therapeutic effects; however, the effect of rRT on PFS is at the lower end of what was reported in scientific publications.

The examination of tumor tissue for the expression of CD95 and CD95L was specified in the study protocol and complemented by the methylation analyses. Both tests were carried out on identical archived tumor samples obtained during surgery at the time of diagnosis and provided quantitative data with an easy to reproduce PCR-based assay. Patients with low methylation levels at CpG2 upstream of *CD95L* showed the best response to treatment with APG101.

These data demonstrate first signs of efficacy of APG101 in combination with rRT. Given the limited options at progression of glioblastoma, rRT+APG101 may represent a therapeutic chance for the subset of patients with the option for second RT. Clinical studies administering



APG101 in combination with radiochemotherapy in newly diagnosed glioblastoma patients will fully exploit the potential of CD95/CD95L inhibition in this disease. In these trials, CD95L promoter methylation will need validation as a potential selection biomarker.

### Disclosure of Potential Conflicts of Interest

W. Wick reports receiving a commercial research grant from Boehringer Ingelheim and Roche; speaker's bureau honoraria from Prime Oncology; and is a consultant/advisory board member for Eli Lilly and Co. and Roche. B. Wiestler is a coinventor of a patent on Neutralization of CD95 activity blocks invasion of glioblastoma cells *in vivo*, which is owned by the German Cancer Research Center and licensed to Apogenix. J. Debus and C. Hartmann report receiving commercial research grants from Apogenix. C. Kunz and Harald Fricke are employees of Apogenix. No potential conflicts of interest were disclosed by the other authors.

### Authors' Contributions

**Conception and design:** W. Wick, H. Fricke, K. Junge, J. Debus, C. Kunz, S.E. Combs

**Development of methodology:** W. Wick, M.G. Schliesser, J. Debus, C. Kunz  
**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** W. Wick, G. Kobayakov, T. Martens, O. Heese, B. Wiestler, M.G. Schliesser, A. von Deimling, J. Pichler, E. Vetlova, I. Harting, J. Debus, C. Hartmann, M. Platten, M. Bendszus, S.E. Combs

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** W. Wick, H. Fricke, K. Junge, O. Heese, B. Wiestler, M.G. Schliesser, J. Debus, C. Hartmann, M. Bendszus, S.E. Combs

**Writing, review, and/or revision of the manuscript:** W. Wick, H. Fricke, G. Kobayakov, O. Heese, B. Wiestler, A. von Deimling, J. Pichler, I. Harting, J. Debus, C. Hartmann, C. Kunz, M. Platten, M. Bendszus, S.E. Combs

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** O. Heese, A. von Deimling, I. Harting

**Study supervision:** W. Wick, E. Vetlova, J. Debus, C. Kunz, S.E. Combs  
**Other (reference pathology molecular reference analyses):** A. von Deimling

### Acknowledgments

The authors are indebted to the patients and their families for agreeing to participate in this trial, as well as to the nurses and data managers for their collaboration. The authors gratefully acknowledge the expertise and time of the members of the study's DSMB [Chair Prof. Roger Stupp (Zurich, Switzerland); members Prof. Minesh Mehta (University of Maryland Medical Center, Baltimore, MD) and Prof. Lee J. Hellman (National Cancer Institute, Bethesda, MD)]. Premier Research (Darmstadt, Germany) served as CRO for monitoring and data collection. The authors also thank Matthias Schick and Roger Fischer from the DKFZ Genomics Core Facility for performing the microarray analyses to a very high standard.

### Grant Support

This work was supported by Apogenix GmbH. The methylation analyses were supported by the Heidelberg Center for Personalized Oncology and Precision Oncology Program (DKFZ HIPO and NCT POP; POP-024).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 17, 2014; revised August 19, 2014; accepted September 4, 2014; published OnlineFirst October 22, 2014.

### References

- Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—are we there yet? *Neuro Oncol* 2013;15:4–27.
- Ohgaki H. Epidemiology of brain tumours. *Methods Mol Biol* 2009; 472:323–42.
- Central Brain Tumour Registry of the United States: 2009–2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumours Diagnosed in Eighteen States in 2002–2006, 2009.
- Batchelor TT, Mulholland P, Neyns B, Nabors LB, Camponi M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. *J Clin Oncol* 2013; 31:3212–8.
- Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. *Lancet Oncol* 2014;15:943–53.
- Wick W, Puduvalli VK, Chamberlain M, van den Bent MJ, Carpentier AF, Cher LM, et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma: a phase III study. *J Clin Oncol* 2010;28:1168–74.
- Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. *J Clin Oncol* 2010;28:2051–7.
- Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. *J Clin Oncol* 2007;25: 3357–61.
- Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single Institution. *J Clin Oncol* 2005;23:8863–9.
- Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. *J Clin Oncol* 2010;28:3048–53.
- Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, et al. CD95 promotes tumour growth. *Nature* 2010;465:492–6.
- Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. *Cancer Cell* 2008;13:235–48.
- Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. *Cancer Res* 2001;61:2759–65.
- Wisniewski P, Ellert-Miklaszewska A, Kwiatkowska A, Kaminska B. Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFκB–TIMP-2 pathway. *Cell Signal* 2009;22:212–20.
- Wild-Bode C, Weller M, Rimmer A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. *Cancer Res* 2001;61: 2744–50.
- Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. *Cancer Res* 2006;66:8511–9.
- Martinou M, Giannopoulou E, Malatara G, Argyriou AA, Kalofonos HP, Kardamakis D. Ionizing radiation affects epidermal growth factor receptor signalling and metalloproteinase secretion in glioma cells. *Cancer Genomics Proteomics* 2004;8:33–8.
- Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. *J Neurooncol* 2006;76:227–37.
- Tuettenberg J, Seiz M, Debatin KM, Hollburg W, von Staden M, Thiemann M, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. *Int Immunopharmacol* 2012;13:93–100.
- Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, et al. CD95-ligand on peripheral myeloid cells activates

- Syk kinase to trigger their recruitment to the inflammatory site. *Immunity* 2010;32:240–52.
21. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. *Nat Med* 2014;20:607–15.
  22. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. *Eur J Cancer* 2006;42:55–64.
  23. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* 1990;8:1277–80.
  24. Wen PY, Macdonald DA, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology (RANO) working group. *J Clin Oncol* 2010;28:1963–72.
  25. Louis DN International Agency for Research on Cancer. WHO classification of tumours of the central nervous system. 4th ed. World Health Organization classification of tumours. Lyon, France: International Agency for Research on Cancer; 2007;309 p.
  26. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. *Acta Neuropathol* 2009;118:599–601.
  27. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. *PLoS ONE* 2012;7:e33449.
  28. Simon R. Designs for efficient clinical trials. *Oncology* 1989;3:43–9.
  29. Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. *Acta Oncol* 2013;8:147–52.
  30. Zheng HX, Cai YD, Wang YD, Cui XB, Xie TT, Li WJ, et al. Fas signaling promotes motility and metastasis through epithelial–mesenchymal transition in gastrointestinal cancer. *Oncogene* 2013;32:1183–92.
  31. de Groot JF, Lamborn K, Chang S, Gilbert MR, Cloughesy TF, Aldape K, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumour Consortium study. *J Clin Oncol* 2011;29:2689–95.
  32. Reardon D, Fink K, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. *J Clin Oncol* 2008;26:5610–7.
  33. van den Bent M, Brandes A, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumour group study 26034. *J Clin Oncol* 2009;27:1268–74.
  34. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. *Int J Radiat Oncol Biol Phys* 2009;63:47–55.
  35. Pfenning PN, Weiler M, Merz C, Jugold M, Gieffers C, Platten M, et al. Inhibition of CD95 signalling by APG101 enhances efficacy of radiotherapy (RT) and reduces RT-induced tumour satellite formation [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011; Washington, DC. Philadelphia (PA): AACR; 2011. Abstract nr LB-382.

# Clinical Cancer Research

## A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

Wolfgang Wick, Harald Fricke, Klaus Junge, et al.

*Clin Cancer Res* 2014;20:6304-6313. Published OnlineFirst October 22, 2014.

**Updated version** Access the most recent version of this article at:  
[doi:10.1158/1078-0432.CCR-14-0951-T](https://doi.org/10.1158/1078-0432.CCR-14-0951-T)

**Supplementary Material** Access the most recent supplemental material at:  
<http://clincancerres.aacrjournals.org/content/suppl/2014/10/23/1078-0432.CCR-14-0951-T.DC1>

**Cited articles** This article cites 32 articles, 14 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/20/24/6304.full#ref-list-1>

**Citing articles** This article has been cited by 3 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/20/24/6304.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/20/24/6304>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.